Stage IV Melanoma: Strategies to Support Shared Decision Making
June 2, 2022
June 1, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and Terranova Medica, LLC.
With additional support from AIM at Melanoma Foundation.
This activity is supported by independent educational grants from Novartis Pharmaceuticals and Merck & Co, Inc.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — 2.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is intended for oncology care providers (including physicians, advanced practice providers, nurses, and other HCPs) who care for patients with melanoma.
The explosion of therapeutic options for Stage IV disease has heralded improved outcomes for patients with Stage IV melanoma. However, this expanded array of available options brings increased complexity for decision making. This activity, Stage IV Melanoma: Strategies to Support Shared Decision Making, uses cases to illustrate state-of-the art management of Stage IV melanoma, with a particular emphasis on how to use the AIM at Melanoma Stage IV melanoma decision-making support tool and Patient Action Plans to support shared decision making. The faculty will also illustrate effective communication strategies in these case simulations. Multidisciplinary approaches will be encouraged, addressing strategies to provide consistent education and engagement across the oncology care team.
Upon completion of this activity, participants should be better able to:
- Describe the factors to consider in promoting shared decision making for stage IV melanoma
- Compare and contrast the efficacy and safety of different therapies for stage IV melanoma
- Incorporate shared decision-making approaches in different stage IV melanoma clinical scenarios
Anna Pavlick, BSN, MSc, DO, MBA
Professor of Medicine in Hematology & Medical Oncology
Weill Cornell Medicine Cutaneous Oncology Program
Anna Pavlick, BSN, MSc, DO, MBA, is a medical oncologist with more than 20 years of experience treating patients with skin cancer, including basal cell and squamous cell carcinoma, melanoma, and Merkel cell carcinoma. She is also an expert in treating ocular melanoma, eyelid tumors, and other rare solid tumor malignancies. Dr Pavlick earned her medical degree from the University of Medicine and Dentistry of New Jersey (UMDNJ)–Robert Wood Johnson Medical School; her Master of Science in human anatomy from Fairleigh Dickinson University; and her Bachelor of Science in biology and nursing from Fairfield University. She completed an internal medicine residency at UMDNJ and hematology and oncology fellowship training at Memorial Sloan Kettering Cancer Center, after which she joined the faculty of Weill Cornell Medicine, New York, NY, as Professor of Medicine in the Division of Hematology & Medical Oncology. She is the founding Director of the Cutaneous Oncology Program there and at New York-Presbyterian Hospital. Dr Pavlick’s major research interests include investigating targeted therapies, combination therapies, and immunotherapies.
Sunandana Chandra, MD, MS
Associate Professor of Medicine in Hematology and Oncology
Northwestern University Feinberg School of Medicine
Dr. Sunandana Chandra is an Associate Professor in Medicine in the Division of Hematology Oncology at Northwestern University. She focuses on advanced cutaneous malignancies and is the Co-Lead of the Northwestern Medicine Skin Disease Team and is a member of their early phase Developmental Therapeutics Program. She recently spearheaded the implementation of an Inpatient Immunotoxicity Consult Service at Northwestern and is a Co-Investigator in the Northwestern Immunotoxicity Biospecimen Registry.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); Terranova Medica, LLC; and AIM at Melanoma Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
- Anna Pavlick, BSN, MSc, DO, MBA
- Grant/Research Support: Replimune
- Speakers Bureau/Honoraria for non-CME: Bristol Myers Squibb
- Consultancy/Advisory Board: Bristol Myers Squibb, Regeneron, Merck
- Sunanda Chandra, MD, MS
- Grant/Research Support: Bristol Myers Squibb, Novartis Pharmaceuticals, Pfizer Inc. Exicure, EMD Serono, Regeneron, Sanfoi-Genzyme
- Consultancy/Advisory Board: Bristol Myers Squibb, Novartis Pharmaceuticals, Pfizer Inc. Exicure, EMD Serono, Regeneron, Sanfoi-Genzyme
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- Register and complete all the sections
- Complete all the online Posttest sections with a score of 75% or better
- Once you complete the Posttest, a link to the evaluation on the CME University website will be unlocked
- On the CME University website, log in or create a new account (will take less than 1 minute)
- If you receive a message when creating a new account that “the email you entered is already in use," please click the Forgot my Username or Password link to have your Username and Password sent to you via email
- After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
- Upon completion of the evaluation, you will receive an immediate CME Certificate to download and/or print for your files
Course Viewing Requirements
Chrome (version 22.0.1229.94 or greater)
Firefox (version 3.6 or greater)
Internet Explorer (version 8.0 or greater)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For further information, contact Tom Davis by telephone (877-276-4523), or by email (firstname.lastname@example.org).
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: email@example.com or (303) 799-1930.